Related Experiment Video
Updated: Jan 20, 2026
The Evidence for Evolution and Common Ancestor
Precision Oncology-The Quest for Evidence
Theodoros G Soldatos1, Sajo Kaduthanam2, David B Jackson3
1Molecular Health GmbH, 69115 Heidelberg, Germany. soldatos@molecularhealth.com.
Abstract:
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk. Numerous innovative precision oncology trials have emerged globally to address the associated need for evidence of clinical utility. These studies seek to capitalize on the power of predictive biomarkers and/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance/response, patient survival, and/or quality of life. Here, we discuss the molecular foundations of these approaches and highlight the diversity of innovative trial strategies that are capitalizing on this emergent knowledge. We conclude that, as increasing volumes of clinico-molecular outcomes data become available, in future, we will begin to transition away from expert systems for treatment decision support (TDS), towards the power of AI-assisted TDS-an evolution that may truly revolutionize the nature and success of cancer patient care.
Insights
Genomic medicine guides cancer treatment, but clinical utility evidence is needed. Innovative trials use biomarkers and analytics to show positive impacts, paving the way for AI-assisted treatment decisions.
Area of Science:
- Oncology
- Genomic Medicine
- Biomarker Discovery
Background:
- Molecular tumor characterization offers a rational approach to cancer treatment decision-making.
- Genomic medicine is emerging, with early adopters facing significant clinical and financial risks.
- Innovative precision oncology trials are crucial for demonstrating clinical utility.
Purpose of the Study:
- To discuss the molecular foundations of precision oncology approaches.
- To highlight diverse innovative trial strategies utilizing emergent knowledge.
- To explore the transition towards AI-assisted treatment decision support.
Main Methods:
- Reviewing molecular characterization in oncology.
- Analyzing innovative precision oncology trial designs.
- Discussing the role of predictive biomarkers and treatment decision support analytics.
Main Results:
- Precision oncology trials aim to demonstrate the impact of biomarkers and analytics on drug response, survival, and quality of life.
- A diversity of innovative trial strategies are capitalizing on molecular insights.
- Increasing clinico-molecular data will drive advancements in treatment decision support.
Conclusions:
- Molecular tumor characterization is foundational for guiding cancer care.
- Innovative trials are essential for validating precision oncology technologies.
- The future of cancer patient care may be revolutionized by AI-assisted treatment decision support.
More Related Videos
Related Concept Videos
The Evidence for Evolution
11:18Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Uncertainty in Measurement: Accuracy and Precision
06:37Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Accuracy and Precision

